Search

Fate Therapeutics Inc

Atvērts

SektorsVeselības aprūpe

2.56

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

2.46

Max

2.59

Galvenie mērījumi

By Trading Economics

Ienākumi

1.1M

-30M

Pārdošana

783K

2.1M

EPS

-0.25

Peļņas marža

-1,448.559

Darbinieki

161

EBITDA

-2.3M

-31M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+162.75% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 12. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-29M

292M

Iepriekšējā atvēršanas cena

2.56

Iepriekšējā slēgšanas cena

2.56

Ziņu noskaņojums

By Acuity

12%

88%

13 / 340 Rangs Healthcare

Fate Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 24. aug. 19:46 UTC

Fate Therapeutics Inc is trading higher amid broader market dynamics influenced by rising oil prices and geopolitical tensions, though no specific news was identified.

2026. g. 22. aug. 00:02 UTC

Fate Therapeutics Inc shares are higher in after-market trading, reflecting broader market gains following recent pressures from rising crude oil prices and bond yields.

2026. g. 20. aug. 20:06 UTC

Correlated Moves

Fate Therapeutics Inc is declining today, mirroring a broader market drop. The stock remains below its 20-day moving average and near its one-month low.

2026. g. 19. aug. 19:26 UTC

Correlated Moves

Fate Therapeutics Inc shares are higher, supported by a significant rise in the ARK Genomic Revolution ETF during Wednesday's session.

2026. g. 14. aug. 19:26 UTC

Event
Social Media
News

Fate Therapeutics has begun its Phase 2 RECLAIM-LN trial for FT819, targeting lupus nephritis. Shares are higher during Friday's session.

2026. g. 13. aug. 23:36 UTC

Fate Therapeutics shares are higher in after-market hours, reflecting a recovery from earlier declines amid broader market optimism regarding the Federal Reserve's interest rate policy.

2026. g. 12. aug. 21:02 UTC

Fate Therapeutics Inc. is gaining in after-market trading, rebounding from three consecutive sessions of declines. The price remains above the 20-day moving average.

2026. g. 7. aug. 20:03 UTC

Fate Therapeutics shares are higher, reaching a session high amid rising U.S. Treasury yields and a weakening U.S. Dollar Index. No specific news identified.

2026. g. 6. aug. 19:26 UTC

Correlated Moves

Fate Therapeutics Inc shares are lower today, reflecting broader market trends and a decline in the Russell 2000 Index amid ongoing inflation concerns.

2026. g. 5. aug. 19:56 UTC

Fate Therapeutics shares are higher amid positive market sentiment and falling oil prices, despite some volatility during Wednesday's trading session.

2026. g. 4. aug. 20:07 UTC

News
Correlated Moves

Fate Therapeutics is gaining as it announces employee inducement awards, including stock options at $2.45 per share. Shares rebounded after an earlier pullback.

2026. g. 3. aug. 23:01 UTC

News

Fate Therapeutics Inc. shares are lower in after-market trading, despite stronger growth in the manufacturing sector and recent employee inducement awards.

2026. g. 29. jūl. 19:19 UTC

Fate Therapeutics is trading higher amid positive market momentum ahead of the Federal Reserve's monetary policy announcement, despite lingering inflation concerns.

2026. g. 28. jūl. 16:06 UTC

Fate Therapeutics shares are lower amid broader market weakness and investor caution ahead of key earnings reports and the Federal Reserve's interest rate decision.

2026. g. 27. jūl. 21:02 UTC

Fate Therapeutics shares are higher in after-market hours, despite no specific news. Broader market sentiment is improving with rising European equity indices.

2026. g. 24. jūl. 19:07 UTC

Correlated Moves

Fate Therapeutics shares are lower, pressured by a notable decline in first-quarter results and broader market sentiment. They remain below the 20-day moving average.

2026. g. 23. jūl. 21:11 UTC

Fate Therapeutics Inc. shares are higher in after-market hours, reflecting broader market gains. No specific company news has been identified to explain this increase.

2026. g. 22. jūl. 23:46 UTC

Fate Therapeutics Inc shares are higher in after-market trading, reflecting a modest gain since Wednesday's close, despite no specific news identified.

2026. g. 20. jūl. 18:26 UTC

Fate Therapeutics Inc. shares are effectively unchanged as trading remains flat. The stock has seen strong performance over the past month, nearing its recent highs.

Salīdzinājums

Cenas izmaiņa

Fate Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

162.75% augšup

Prognoze 12 mēnešiem

Vidējais 6.7 USD  162.75%

Augstākais 8 USD

Zemākais 3.5 USD

Pamatojoties uz 7 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Fate Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

7 ratings

4

Pirkt

3

Turēt

0

Pārdot

Noskaņojums

By Acuity

13 / 340 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
help-icon Live chat